UCB Sponsored Symposium


Monday 29th April 2024 18:45 – 19:30 GMT

Long Term Data Update on Bimzelz for PsO

Speaker: Lucy Moorhead, Nurse Consultant in Inflammatory Skin Disease, Guys and St Thomas’ NHS Trust

This promotional webinar is initiated and funded by UCB Pharma Ltd and is open to United Kingdom and Republic of Ireland healthcare professionals only. UCB products will be discussed.

Click here for GB Prescribing Information
Click here for NI & ROI Prescribing Information

BIMZELX® is indicated for moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Alone or in combination with methotrexate, for active psoriatic arthritis in adults who have had an inadequate response or intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).

Click here to register

GB-BK-2400197 | Date of preparation: March 2024
© UCB Biopharma SRL, 2024. All rights reserved.
This promotional webinar has been initiated and funded by UCB Pharma Ltd